1239729-06-6

物理化學(xué)性質(zhì)
報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
2025/02/08 | HY-109112 | Brilaroxazine | 1239729-06-6 | 1 mg | 1350元 |
2025/02/08 | HY-109112 | RP-5063 Brilaroxazine | 1239729-06-6 | 10 mM * 1 mLin DMSO | 3171元 |
2025/02/08 | HY-109112 | RP-5063 Brilaroxazine | 1239729-06-6 | 5 mg | 3200元 |
常見問題列表
5-HT 1A Receptor 1.5 nM (Ki) |
5-HT 2A Receptor 2.5 nM (Ki) |
5-HT 2B Receptor 0.19 nM (Ki) |
5-HT 7 Receptor 2.7 nM (Ki) |
D 2 Receptor
|
D 3 Receptor
|
D 4 Receptor
|
Brilaroxazine (oral gavage; 10 mg/kg; twice daily; 28 days) limits the functional and structural effects of pulmonary arterial hypertension (PAH), with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO2, and pulmonary blood vessel structural changes.
Animal Model: | SD-rats |
Dosage: | 10 mg/kg |
Administration: | Oral gavage; twice daily; 28 days |
Result: | Had the efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH. |